(Rac) -Apremilast

(Rac) -Apremilast ((Rac) -CC-10004) is the racemic mixture of Apremilast. (Rac) -Apremilast has anti-inflammatory properties and can be used for research on inflammatory diseases, such as psoriasis[1][2].

Product Specifications

CAS Number

[253168-86-4]

Product Name Alternative

(Rac) -CC-10004

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Phosphodiesterase (PDE)

Type

Reference compound

Related Pathways

Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/rac-apremilast.html

Purity

99.53

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

CC(NC1=CC=CC(C(N2C(C3=CC=C(OC)C(OCC)=C3)CS(=O)(C)=O)=O)=C1C2=O)=O

Molecular Formula

C22H24N2O7S

Molecular Weight

460.50

Precautions

H302, H315, H319, H335

References & Citations

[1]Armstrong AW, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023 Jan;88 (1) :29-39. |[2]Man H W, et al. Discovery of (S) -N-{2-[1- (3-ethoxy-4-methoxyphenyl) -2-methanesulfonylethyl]-1, 3-dioxo-2, 3-dihydro-1 H-isoindol-4-yl} acetamide (apremilast), a potent and orally active phosphodiesterase 4 and tumor necrosis factor-α inhibitor[J]. Journal of medicinal chemistry, 2009, 52 (6) : 1522-1524.